Crossmark

Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease

Crossref DOI link: https://doi.org/10.1007/s00296-024-05571-y

Published Online: 2024-03-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Farina, Nicola https://orcid.org/0000-0001-7650-2582
Tomelleri, Alessandro https://orcid.org/0000-0002-5440-2078
Boffini, Nicola https://orcid.org/0000-0002-4416-933X
Cariddi, Adriana

Calvisi, Stefania https://orcid.org/0000-0002-9685-4582
Baldissera, Elena https://orcid.org/0000-0002-9292-3851
Matucci-Cerinic, Marco https://orcid.org/0000-0002-9324-3161
Dagna, Lorenzo https://orcid.org/0000-0002-7428-315X
License Information

Text and Data Mining valid from 2024-03-20

Version of Record valid from 2024-03-20
More Information

Article History

Received: 28 December 2023

Accepted: 26 February 2024

First Online: 20 March 2024

Declarations

:

: AT, NB, EB, MMC, LD received consultation honoraria from Novartis.